The Venture Capital Podcast with Fexingo · 2026-07-21 · 9 min
Colossal Biosciences is reportedly raising at a $20B to $30B valuation. Lucas and Luna break down the venture logic behind de-extinction: the science, the spinouts in gene editing and synthetic biology, and the parallels to longevity biotech. They examine whether Colossal's valuation is backed by real platform potential or hype, referencing the latest headlines and the broader VC appetite for frontier tech. The episode also touches on how VCs underwrite risk when the product is resurrecting the woolly mammoth. #DeExtinction #ColossalBiosciences #VentureCapital #StartupInvesting #GeneEditing #SyntheticBiology #LongevityBiotech #Biotech #Valuation #FrontierTech #Science #Business #Technology #FexingoBusiness #BusinessPodcast #VCPodcast #TermSheets #Startup Keep every episode free: buymeacoffee.com/fexingo
Other episodes covering the same guests and topics, from across The B2B Podcast Index.